Question explored with the scientific record
Ibuprofen until 6 weeks pregnancy, is it ok
Ibuprofen in the first six weeks of pregnancy carries real, documented risks to the pregnancy itself.
The strongest evidence comes from a 2018 study that directly measured miscarriage risk. Women who used NSAIDs like ibuprofen around conception had a miscarriage rate of 24.1%, compared to 17.0% in unexposed women [2]. The risk was especially high for miscarriages before 8 weeks gestation, with a hazard ratio of 4.08 [2]. A 2012 study also found small-to-moderate links between first-trimester ibuprofen use and specific birth defects like anophthalmia/microphthalmia (odds ratio 1.9) and oral clefts [1]. A 2025 mouse study showed that NSAIDs given before implantation disrupted embryo spacing and led to embryo crowding, impaired blood vessel remodeling, and a drop in litter size from 10 pups to 4 [3]. The mechanism is clear: ibuprofen blocks prostaglandin synthesis, and prostaglandins are essential for implantation, uterine blood flow, and early development [4, 5].
The evidence for benefit in this context is absent. Ibuprofen treats pain and inflammation, but there is no study showing it prevents any pregnancy complication in the first six weeks. The risks are to the pregnancy itself, not just to the fetus later on.
| Outcome | NSAID-exposed | Unexposed | Risk increase |
|---|---|---|---|
| Miscarriage rate | 24.1% [2] | 17.0% [2] | ~40% relative increase |
| Miscarriage before 8 weeks | Hazard ratio 4.08 [2] | - | 4-fold higher risk |
| Anophthalmia/microphthalmia | OR 1.9 [1] | - | Small-to-moderate increase |
My call: ibuprofen is not worth the risk in the first six weeks of pregnancy. The miscarriage signal is strong, the mechanism is biologically plausible, and there is no countervailing benefit for the pregnancy. Confidence: moderate — the miscarriage data comes from a single well-designed study, and the birth defect evidence is from case-control data with potential recall bias, but the consistency across human and animal studies is concerning.
Sources used 5
-
Nonsteroidal antiinflammatory drug use among women and the risk of birth defects
This multisite population-based case-control study using data from the National Birth Defects Prevention Study assessed first-trimester NSAID use and found no major overall increase in birth defects, though small-to-moderate associations were observed for certain defects with as…
DOI: 10.1016/j.ajog.2011.11.019 -
Use of nonsteroidal antiinflammatory drugs during pregnancy and the risk of miscarriage
This study investigates the association between nonsteroidal antiinflammatory drug (NSAID) use during early pregnancy and the risk of miscarriage, finding a significant increase in risk particularly around conception and a dose-response relationship.
DOI: 10.1016/j.ajog.2018.06.002 -
Pre-implantation non-steroidal anti-inflammatory drug treatment disrupts mouse embryo spacing and post-implantation chamber morphogenesis
Pre-implantation indomethacin, a non-selective COX inhibitor, disrupts mouse embryo spacing and implantation chamber morphogenesis in a dose-dependent manner, leading to delayed implantation, embryo crowding, impaired vascular remodeling, mid-gestation embryo loss, and reduced l…
DOI: 10.1101/2025.11.02.686054 -
Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
A comprehensive narrative review detailing how prenatal exposure to non-steroidal anti-inflammatory drugs (NSAIDs) crosses the placenta, the mechanisms involved, and the wide range of embryo-fetal and neonatal adverse effects that can occur depending on timing, dose, and duratio…
DOI: 10.2174/138920012800166607 -
Inhibition of prostaglandin synthesis and contractility in the rabbit and rat uterus by ibuprofen
This study investigates the effects of Ibuprofen on prostaglandin synthesis and contractility in the rabbit and rat uterus, demonstrating significant reductions in uterine tension and prostaglandin levels, particularly in postpartum rabbits.
DOI: 10.1016/0090-6980(77)90246-5